Flublok Quadrivalent vaccine is proven in a head-to-head randomized controlled trial to prevent more cases of laboratory-confirmed influenza in adults 50+ compared with a standard-dose quadrivalent inactivated influenza vaccine.1,2

Indication for Flublok Quadrivalent Vaccine

Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza A subtype viruses and influenza type B viruses contained in the vaccine. Flublok Quadrivalent is approved for use in persons 18 years of age and older.1


Proven Efficacy

According to the randomized controlled study of more than 9,000 adults 50+, during the 2014-2015 flu season, Flublok Quadrivalent vaccine provided1,2:

Primary Endpoint
30%
Better Protection
from Influenza
compared with a standard-dose quadrivalent inactivated influenza vaccine1,2
The primary endpoint of the study was PCRa-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype.

aPCR = Polymerase chain reaction.

Secondary Endpoint
43%
Better Protection
from Influenza
compared with a standard-dose quadrivalent inactivated influenza vaccine1,2
The secondary endpoint of the study was culture-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype.

In this randomized controlled trial, the most common local and systemic adverse reactions to Flublok Quadrivalent vaccine include pain at the injection site, headache and fatigue.1,2

Safety Information

Flublok Quadrivalent vaccine was compared with a standard-dose quadrivalent inactivated influenza vaccine in adults 50+1


Fluzone Quadrivalent Vaccine Injection-Site and System Reactions Fluzone Quadrivalent Vaccine Injection-Site and System Reactions
  • Studied in a randomized, controlled, head-to-head trial with results published in the New England Journal of Medicine2
    • In adults 50+ (N=8,672)1
    • Across multiple strains of influenza: A (H1N1), A (H3N2), and B/Yamagata and B/Victoria1
    • With vaccine components that were well matched or not well matched to the circulating strains1
    • In the 2014-2015 flu season, epidemiological data indicated that influenza A (H3N2) viruses predominated and most were antigenically dissimilar while A (H1N1) and B viruses were antigenically similar to vaccine antigens1
  • The only quadrivalent influenza vaccine to provide all of these features:
    • FDA-licensed recombinant hemagglutinin (HA) influenza vaccine1
      • Replicates the recommended influenza strains exactly2
    • 3X the HA (45 mcg HA per strain) of a standard-dose quadrivalent inactivated influenza vaccine1
    • Comparable safety profile to a standard-dose quadrivalent inactivated influenza vaccine2
    • Approved for adults 18 years of age and older1